Accordingly, use of two such antagonists, Maraviroc (a CCR5 antagonist) for the treatment of HIV/AIDS [17] and Plerixafor (a CXCR4 antagonist) used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma have been approved by the United States Food and Drug Administration (FDA) [18]. This evidence concerns the gene CSF3 and plasma cell myeloma.